The deal focuses on developing five mRNA-based vaccines and monoclonal antibodies to prevent and treat infectious diseases. CureVac, which is backed by Microsoft founder Bill Gates, was targeted for the deal due to its advancement in mRNA technology and RNA manufacturing capabilities.
The deal will not involve GSK with CureVac’s existing COVID-19 mRNA and rabies vaccine research programs.
“GSK’s self-amplifying mRNA (SAM) vaccine technology has shown us the potential of mRNA technology to advance the science of vaccine development, and CureVac’s experience complements our own expertise,” Roger Connor, president of GSK’s vaccine division, said in a news release. “Through the application of mRNA technology, including SAM, we hope to be able to develop and scale up advanced vaccines and therapies to treat and prevent infectious diseases quicker than ever before.”
More articles on pharmacy:
Medical researchers sign open letter calling for COVID-19 human challenge trials
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma
Medical researchers sign open letter calling for COVID-19 human challenge trials
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.